

Table 7.6g
Immunosuppression Use for Maintenance Between Discharge
and One Year Following Transplantation, 1999 to 2008
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	220	305	305	375	344	420	343	293	261	213
Tx with Follow-up Immunosuppression Info	167	220	245	271	257	321	255	220	205	166
Corticosteroids										
Any in Category	100.0%	98.6%	98.8%	94.5%	78.6%	73.8%	74.9%	70.9%	60.0%	64.5%
Steroids	100.0%	98.6%	98.8%	94.5%	78.6%	73.8%	74.9%	70.9%	60.0%	64.5%
Cyclosporine										
Any in Category	14.4%	16.4%	15.1%	15.1%	11.3%	8.1%	6.7%	6.8%	5.9%	7.8%
Sandimmune	2.4%	3.2%	0.8%	1.1%	0.0%	0.3%	0.0%	0.5%	0.5%	0.6%
Neoral	12.0%	12.3%	12.7%	11.8%	9.3%	5.0%	6.3%	6.4%	5.4%	6.0%
Gengraf	0.0%	0.9%	0.8%	2.2%	1.6%	2.8%	0.4%	0.0%	0.0%	1.2%
Eon	0.0%	0.0%	0.8%	0.0%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%
Tacrolimus										
Any in Category	91.0%	91.8%	91.8%	87.5%	82.9%	87.2%	92.5%	91.8%	93.7%	92.2%
Tacrolimus	91.0%	91.8%	91.8%	87.5%	82.9%	87.2%	92.5%	91.8%	93.2%	91.6%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.6%
Antimetabolites										
Any in Category	95.2%	84.5%	80.4%	80.4%	84.8%	82.6%	90.6%	87.3%	90.2%	89.2%
Mycophenolate Mofetil	86.2%	78.6%	78.0%	78.2%	80.9%	79.4%	84.3%	75.5%	75.6%	69.9%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	4.3%	8.6%	12.2%	14.5%
Azathioprine	9.0%	5.9%	2.4%	2.2%	3.5%	0.3%	2.0%	1.8%	1.0%	4.2%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%	0.0%	1.4%	1.5%	0.6%
Cytosan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitors										
Any in Category	7.2%	24.5%	30.6%	31.7%	27.2%	25.5%	19.2%	17.3%	19.0%	16.3%
Sirolimus	7.2%	24.5%	30.6%	31.7%	27.2%	25.5%	19.2%	17.3%	19.0%	16.3%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation. Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.